Novo Nordisk’s 20% Run Hinges on FDA and the Race to Replace Ozempic
Published on 07/03/2026 at 21:54 | Redaktion boerse-global.de
Novo Nordisk has clawed back sharply from its March lows, with the stock now trading at EUR 44.03 — a 19.52% gain over the past 30 days. The rebound from the 52-week trough of EUR 30.25 amounts to a 43.80% recovery, yet the shares still sit 28.92% below last July’s record of EUR 61.20. Beneath the surface-level rally, however, the company is facing a structural test: management itself expects revenue to decline meaningfully in 2026 as older products face pricing pressure and competition. The entire bull case now rests on whether next-generation therapies can scale fast enough to fill that gap.
The Wegovy Pill: Prescriptions Surge, Production Ramps Up
The oral version of Wegovy has been a bright spot. Since its U.S. launch in January, more than 1 million patients started taking it within the first four months, and total prescriptions have already eclipsed 3 million. The European Medicines Agency’s CHMP recently issued a positive opinion for the pill in the EU, with final approval from the European Commission still pending. Novo is racing to boost supply, investing EUR 432 million in its Athlone, Ireland, facility and building a new multi-billion-dollar plant in the United States. On top of that, the FDA is currently reviewing a higher 7.2-milligram dose of oral Wegovy, which could further broaden its appeal.
CagriSema: The Real Catalyst Hinges on FDA
While the pill generates near-term momentum, the biggest swing factor remains CagriSema, the company’s next-generation obesity injectable. Novo filed for U.S. approval in December 2025, with a decision expected in the second half of 2026 — no formal PDUFA date has been confirmed. The submission rests on the REDEFINE 1 and REDEFINE 2 studies. But a direct head-to-head trial, REDEFINE 4, failed to show non-inferiority against Eli Lilly’s Zepbound (tirzepatide) over 84 weeks: CagriSema 2.4 mg led to a 23.0% weight loss versus Zepbound 15 mg’s 25.5%. That clinical miss has cast a shadow, though it is not a regulatory verdict. In a separate study (REIMAGINE), CagriSema outperformed Novo’s own semaglutide, yielding 14.2% weight loss over 68 weeks compared with 10.2% for the older drug.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Bearish Headwinds: Market Share Loss, Medicare, and Patents
The competitive landscape is growing more hostile. Eli Lilly now commands roughly 60% of the U.S. GLP-1 market, leaving Novo with an estimated 40%. Lilly recently launched its own oral obesity drug, Foundayo, which has the advantage of not requiring an empty stomach — a direct threat to the Wegovy pill. Meanwhile, Medicare is forcing price cuts on Ozempic and Wegovy, and several international patents are set to expire, opening the door for generics. Morgan Stanley analyst Thibault Boutherin continues to prefer Lilly over Novo, citing superior efficacy data for Zepbound and Mounjaro and the added pressure from generic competition.
Technically, the rally looks stretched. The Relative Strength Index has climbed to 75.9, well into overbought territory — earlier readings of 71.6 had already raised flags. The stock is trading nearly 14% above its short-term moving average of EUR 38.73, making it vulnerable to a pullback on any negative news.
Key Dates on the Horizon
The next concrete milestones are just weeks away. Novo will report first-half results on August 5, followed by a capital markets day on September 21, where investors expect detailed timelines for CagriSema’s launch and label expectations. Until then, the share price is likely to swing between bullish pipeline hopes and harsh financial realities. If the Wegovy pill continues to gain traction and no further negative signals emerge from the FDA review, the stock could consolidate near current levels, with the 50-day moving average around EUR 38.72 acting as support. But if Lilly’s oral Foundayo gains share faster than anticipated, or if the CagriSema label disappoints, a correction toward the EUR 38 mark — near the 200-day line at EUR 40.80 — looked plausible. For now, Novo Nordisk is in a high-stakes waiting game, betting that its pipeline can outrun a looming revenue cliff.
Ad
Novo Nordisk Stock: New Analysis - 3 July
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
